3rd retraction appears for fired Pfizer breast cancer researcher

Pfizer has retracted a paper by a former employee who was fired after the company discovered she had been doctoring data.

The retraction, in Molecular Cancer Research, is the third of five papers Pfizer asked to retract, after an investigation discovered they contained duplicated images. The papers have been discussed on PubPeer, which is also mentioned in the latest retraction notice.

As a result of the investigation, Pfizer terminated the employment of Min-Jean Yin, the last author on the newly retracted paper.

According to the notice, Yin and five of her co-authors agreed to the retraction:

Continue reading 3rd retraction appears for fired Pfizer breast cancer researcher

Researcher who lost whistleblower lawsuit logs 4 more retractions

A brain journal has retracted four papers by a researcher due to image duplications that the university uncovered during an investigation into his work.

According to the retraction notice, Wayne State University found that Christian Kreipke had used several images in these articles “to represent different results in grant proposals and/or poster presentations,” and that the data were unreliable. Kreipke now has a total of five retractions, by our count.

As we’ve reported before, Wayne State and Kreipke have been engaged in conflict for several years. In 2012, Kreipke was dismissed from his assistant professor post at Wayne State after the university said it found evidence of research misconduct, according to Courthouse News. Kreipke fired back against the university, filing a whistleblower lawsuit. In it, Kreipke claimed that the institution was “involved in a conspiracy,” according to unsealed court documents, in which it had swindled the U.S. government out of millions in research funding.

A judge dismissed the case in 2014, but the conflict between Kreipke and Wayne State was not over. Continue reading Researcher who lost whistleblower lawsuit logs 4 more retractions

Unexplained abnormalities in stem cells prompt Columbia researchers to pull diabetes paper

Researchers at Columbia University have retracted a 2013 paper in The Journal of Clinical Investigation, after uncovering abnormalities in the stem cell lines that undermined the conclusions in the paper.

Last year, corresponding author Dieter Egli discovered he could not reproduce key data in the 2013 paper because almost all the cell lines first author Haiqing Hua used contained abnormalities, casting doubt on the overall findings. When Egli reached out to Hua for answers, Hua could not explain the abnormalities. As a result, Hua and Egli agreed the paper should be retracted.

Since some of the details of how the paper ended up relying on abnormal cells remain unclear, the university confirmed to us that it is investigating the matter.

Here’s the retraction notice for “iPSC-derived β cells model diabetes due to glucokinase deficiency,” cited 42 times: Continue reading Unexplained abnormalities in stem cells prompt Columbia researchers to pull diabetes paper

When you have 94 retractions, what’s two more?

Attention Joachim Boldt: The 1990s are calling, and they want their papers back.

The Annals of Thoracic Surgery has retracted two papers from the early 1990s on which Boldt was the first author – bringing the retraction tally for the disgraced German anesthesiologist to 96, by our count. Both articles were found to contain manipulated data.

The first paper, from 1990, was titled “Acute Preoperative Plasmapheresis and Established Blood Conservation Techniques,” and was written when Boldt was on the faculty at Justus-Liebig University, in Giessen.

According to the notice:

Continue reading When you have 94 retractions, what’s two more?

Coauthor’s past misconduct prompts dep’t chair to retract Diabetes study

A department chair of a Swedish university asked to retract a 2010 study in Diabetes after none of the authors could explain image-related ambiguities.

The matter prompted particular attention because the paper’s first author, Pontus Almer Boström, had been found guilty of scientific misconduct by the University of Gothenburg in 2012, after Jan Borén noted some irregularities in data calculated by Boström. At that point, the research group combed the data to identify further issues arising from Boström’s work, and didn’t find any.

But last summer, when a user on PubPeer raised questions about some of the images in the 2010 paper, the matter was brought back into focus. According to Borén, they found “no evidence of scientific misconduct in this study.” But Boström had left the university in 2009 and could not be reached, the corresponding author had passed away, and the remaining co-authors hadn’t stayed in the field. So Borén decided it would be best to retract the study to avoid any “lingering questions.”

Here’s the retraction notice for “The SNARE Protein SNAP23 and the SNARE-Interacting Protein Munc18c in Human Skeletal Muscle Are Implicated in Insulin Resistance/Type 2 Diabetes,” in which Borén thanks “Peer 1″ on PubPeer for “detecting the ambiguities and bringing them to our attention:” Continue reading Coauthor’s past misconduct prompts dep’t chair to retract Diabetes study

Does labeling bad behavior “scientific misconduct” help or hurt research integrity? A debate rages

Is eliminating the concept of “misconduct” a sign of progress in the fight for research integrity, or a step backward?

That’s the debate playing out in Australia, where a proposal from national research bodies would make it the latest country to embrace a broader definition of ethical lapses in research, doing away with the term “misconduct.” Proponents argue the change will encourage more reporting of all types of bad behavior—not just the most extreme forms such as data fabrication, which are typically associated with the term “misconduct.” But critics argue the move could soften enforcement, as every institution applies its own definitions of misbehavior. (To tell us what you think, take our poll at the bottom of the story.)

The proposal comes in the form of a revised edition of Australia’s national research code of conduct.  Continue reading Does labeling bad behavior “scientific misconduct” help or hurt research integrity? A debate rages

Unusual: Neurology removes author dinged for misconduct from 2016 paper

Neurology has partially retracted a 2016 paper, replacing a figure and removing the author who contributed it after he was found guilty of misconduct.

The journal has replaced the figure with a new one that confirmed the findings of the original, and swapped the name of Andrew Cullinane with the scientist who constructed the new figure using a new dataset. Last year, the U.S. Office of Research Integrity declared that Cullinane had falsified data in this paper and one other while working as a postdoctoral fellow in the Medical Genetics Branch at the National Human Genome Research Institute (NHGRI).

Cullinane appears to be at Howard University in Washington D.C., according to his LinkedIn page. He is listed as an assistant professor in the Basic Sciences/Anatomy department of the university’s College of Medicine.

Here’s the partial retraction notice from the journal:

Continue reading Unusual: Neurology removes author dinged for misconduct from 2016 paper

Cancer biologist stops research as his retraction count rises to 13

Anil Jaiswal

A cancer biologist based at the University of Maryland is transitioning out of research, as a journal has retracted three more of his papers.

Anil Jaiswal has now lost 13 papers, including, as we reported on February 6, six retractions issued earlier this month.

The Baltimore Sun reported this week that Jaiswal would no longer be conducting research at the University of Maryland School of Medicine, which we confirmed from a spokesperson:

Continue reading Cancer biologist stops research as his retraction count rises to 13

Researcher sued to stop retractions; he just earned two more and is now up to 11

The notices keep coming for diabetes researcher Mario Saad.

Diabetes has just retracted two more of his papers, both of which had been flagged by expressions of concern, citing problems with duplications. What’s more, the journal added another expression of concern to a 2009 paper on which Saad — based at the University of Campinas in São Paulo, Brazil — is listed as last author, again over concerns of duplication.

This isn’t Saad’s first run-in with the journal: In 2015, the researcher sued the publisher, the American Diabetes Association, after it issued expressions of concern for four of his papers. Later that year, a judge dismissed Saad’s defamation suit. The journal eventually retracted the papers.

The latest articles flagged by Diabetes appear to be part of an intricate publishing web, as the journal suggests all papers have used features of previous papers, and also include elements that have been republished by subsequent articles.

Here’s the first retraction notice, for “A Central Role for Neuronal AMP-Activated Protein Kinase (AMPK) and Mammalian Target of Rapamycin (mTOR) in High-Protein Diet–Induced Weight Loss:”

Continue reading Researcher sued to stop retractions; he just earned two more and is now up to 11

Journal pulls paper with missing data, citing inquiry and legal proceedings

A journal has retracted a 2012 paper after the last author was unable to provide material to support the results presented in multiple figures.

The lack of supporting data came out during “an internal inquiry and subsequent legal proceedings,” according to the notice, issued by Cell Cycle.

The last author on the paper is Susana Gonzalez, who was dismissed from her position at the National Center for Cardiovascular Research (CNIC) in Spain last year.

Here’s the full notice:

Continue reading Journal pulls paper with missing data, citing inquiry and legal proceedings